Your search for smoking cessation returned 200 results

Study shows that all behavioral outcomes favor e-cigarette users across the motivational spectrum for quitting.

Cytisinicline well tolerated with only 2.9% of participants discontinuing due to an adverse event.

No significant difference in verified 7-day abstinence seen by treatment group among Black adults who smoke daily.

The Nicotrol Inhaler (nicotine inhalation system) has been discontinued by Pfizer.

N-nitroso-varenicline may be associated with an increased cancer risk based on data from closely related nitrosamine compounds.

Significantly fewer adverse reactions reported by those in the cytisine group versus the varenicline group.

High quality communication in tobacco treatment programs with lung cancer screenings was significantly associated with self-efficacy for smoking cessation.

Guideline offers simple practice changes that may increase effectiveness of tobacco-dependence pharmacotherapy.

One-year abstinence higher with e-cigarettes than other nicotine replacement products

E-cigarette use was 9.8% among current smokers, 1.1% among former smokers, and 0.6% among nonsmokers.